12/31
02:44 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/23
02:07 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/19
05:28 pm
apto
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Canadian Business Journal (Canada)]
High
Report
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Canadian Business Journal (Canada)]
12/19
04:17 pm
apto
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Yahoo! Finance]
High
Report
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Yahoo! Finance]
12/19
04:05 pm
apto
Aptose Announces Positive Decision by Nasdaq Hearings Panel
High
Report
Aptose Announces Positive Decision by Nasdaq Hearings Panel
12/15
02:01 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/12
10:15 am
apto
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Low
Report
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
12/10
08:01 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
12/9
12:07 pm
apto
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML [Yahoo! Finance]
Low
Report
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML [Yahoo! Finance]
12/9
12:00 pm
apto
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Low
Report
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
12/7
02:04 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/3
12:52 pm
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
12/3
07:35 am
apto
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials [Yahoo! Finance]
Low
Report
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials [Yahoo! Finance]
12/3
07:30 am
apto
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
High
Report
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
11/29
03:07 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/25
04:15 pm
apto
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Low
Report
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
11/22
09:28 am
apto
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering [Canadian Business Journal (Canada)]
High
Report
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering [Canadian Business Journal (Canada)]
11/22
08:11 am
apto
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering [Yahoo! Finance]
High
Report
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering [Yahoo! Finance]
11/22
08:00 am
apto
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
Medium
Report
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
11/21
03:06 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/20
01:16 pm
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.00. They now have a "buy" rating on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at HC Wainwright from $7.00 to $2.00. They now have a "buy" rating on the stock.
11/20
07:39 am
apto
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy [Yahoo! Finance]
High
Report
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy [Yahoo! Finance]
11/20
07:30 am
apto
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
High
Report
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
11/13
03:01 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/8
05:28 pm
apto
Aptose Reports Results for the Third Quarter 2024 [Canadian Business Journal (Canada)]
Low
Report
Aptose Reports Results for the Third Quarter 2024 [Canadian Business Journal (Canada)]